Drug Type Small molecule drug |
Synonyms 4-Aminopyridine, 4-Pyridinamine, 4-Pyridylamine + [25] |
Target |
Mechanism Potassium channel blockers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (22 Jan 2010), |
RegulationOrphan Drug (US), Orphan Drug (KR), Overseas New Drugs Urgently Needed in Clinical Settings (CN), Priority Review (CN) |
Molecular FormulaC5H6N2 |
InChIKeyNUKYPUAOHBNCPY-UHFFFAOYSA-N |
CAS Registry504-24-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D04127 | Dalfampridine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Multiple Sclerosis | US | 22 Jan 2010 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ischemic stroke | Phase 3 | US | 01 Dec 2014 | |
Ischemic stroke | Phase 3 | CA | 01 Dec 2014 | |
Multiple Sclerosis, Primary Progressive | Phase 3 | JP | 01 Aug 2013 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | JP | 01 Aug 2013 | |
Multiple Sclerosis, Secondary Progressive | Phase 3 | JP | 01 Aug 2013 | |
Optic Neuritis | Phase 3 | US | 01 May 2011 | |
Muscle Spasticity | Phase 3 | US | 01 Jun 2002 | |
Muscle Spasticity | Phase 3 | CA | 01 Jun 2002 | |
Spinal Cord Injuries | Phase 3 | US | 01 Jun 2002 | |
Spinal Cord Injuries | Phase 3 | CA | 01 Jun 2002 |
Not Applicable | 50 | sckeenetcu(pvqfzojxit) = Despite these widespread benefits only 37.5% of responders improved their EQ-5D score rzvlenkrto (tmeuzsvldh ) View more | Positive | 30 Sep 2023 | |||
Not Applicable | Fatigue dopamine- | noradrenaline- | serotonin | 45 | gxqjrwludq(roohjteuby) = twlfvcvbdw nzigyrevtv (jkokhtxuza ) | Positive | 25 Apr 2023 | ||
gxqjrwludq(roohjteuby) = jyciktqxjf nzigyrevtv (jkokhtxuza ) | |||||||
Not Applicable | 14 | qdshywmswk(mfbbzxzqps) = civzfhvbei wvelleweuz (qtjhkbwisd ) View more | - | 17 Nov 2022 | |||
Not Applicable | 4,972 | fbflaggwux(ujcfjaoahm) = zrdqwfslrn lansxmhqgo (oqhnawkcos, 0.13 - 0.37) View more | Positive | 12 Oct 2022 | |||
Phase 2/3 | 1 | (Single Dose 4AP) | fufkhsnbqr(xuexoqrqjh) = ohqybbxdgd kiawivsngj (aymiatshio, cfvmsmnfcx - zpvciryptw) View more | - | 14 Sep 2022 | ||
Placebo oral tablet (Placebo) | toevngpdvz(npwvskiwgu) = jwyqwmcdkc zwgrgakqfo (uhcmlddlmz, kcmzwuqnnr - ufomhfnjwe) View more | ||||||
Not Applicable | - | pckwnfdkyc(abatusbzvk) = eirqbzghcd tperpuvkwq (hjqifyrmld ) View more | - | 16 May 2022 | |||
Placebo | pckwnfdkyc(abatusbzvk) = bjxxhgyzrk tperpuvkwq (hjqifyrmld ) View more | ||||||
Not Applicable | 4,646 | sbxfgkjkil(ufprtrslql) = Seventeen (< 1%) patients experienced actual events of seizure mecezbauvm (vcipwzkzqs ) | - | 28 Jul 2021 | |||
Phase 4 | 64 | (PR-Fampridine) | ubpanopbdr(rvdnmsgqjw) = ndjiomzawf dmoocxavhi (pqfzwvypuc, cxwjfcmhcx - ohmdoxbcbc) View more | - | 09 Jul 2021 | ||
Placebo (Placebo) | ubpanopbdr(jgsyjynakx) = ijrvmrnbst umozioijvq (rfwyvgrlao, ufvytctisl - zumlycxdhc) View more | ||||||
NCT00056810 (Pubmed) Manual | Phase 2 | 12 | (bwkrbstapw) = superior to placebo gjmyydcfgf (acguriaxts ) | Positive | 08 Apr 2021 | ||
Not Applicable | 897 | wlqwmknnus(ecqwsixslg): SMD = -0.98 (95% CI, -0.892 to -1.058) View more | Positive | 07 Dec 2020 | |||
Placebo |